SOPHiA GENETICS S.A.
SOPHiA GENETICS S.A.（SOPH）股东结构
基于 13F 申报与流通股数据，展示机构、内部人与公众持股结构；下方为前十大机构、机构动向与内部人交易。
SEC 13F · FMP · SOPH · 截至 2025年9月30日
股东结构概览
40
机构持有人数
▲ 8 vs Q2
$84.31M
机构持仓总市值
▲ $33.08M vs Q2
71.67M
总流通股
freeFloat 72.16%
17.71M
13F 申报持股数
▲ 1.19M vs Q2
机构持仓% = 13F 持股数 ÷ 总流通股。内部人% = 100 − 自由流通率。散户% = 自由流通率 − 机构%。数据来源：FMP /symbol-positions-summary + /shares-float + SEC EDGAR。
前10大机构持仓
SOPH 最大股东 · 机构持仓
Q3 2025 · SEC 13F
显示前 10 家
| 机构 | 持股数 | 占比 | 权重 | 市值 | 申报日 | 变动 |
|---|---|---|---|---|---|---|
GENERATION INVESTMENT MANAGEMENT LLP biological products, (no diagnostic substances) | 6.79M | 10.09% | 10.09% | $32.32B | Nov 10, 2025 | — held |
AKRE CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 3.72M | 5.52% | 5.52% | $17.70B | Nov 13, 2025 | — held |
BANQUE PICTET & CIE SA biological products, (no diagnostic substances) | 2.21M | 3.28% | 3.28% | $10.51B | Oct 21, 2025 | — held |
ALTA WEALTH ADVISORS LLC biological products, (no diagnostic substances) | 1.41M | 2.09% | 2.09% | $6.71B | Nov 3, 2025 | ▲ 1.41M |
PRINCIPAL FINANCIAL GROUP INC biological products, (no diagnostic substances) | 1.39M | 2.07% | 2.07% | $6.62B | Nov 4, 2025 | ▼ 9.0K |
ARCHON CAPITAL MANAGEMENT LLC biological products, (no diagnostic substances) | 427.1K | 63.44% | 63.44% | $2.03B | Nov 14, 2025 | ▲ 105.5K |
PICTET & CIE (EUROPE) SA biological products, (no diagnostic substances) | 255.2K | 37.91% | 37.91% | $1.21B | Oct 21, 2025 | — held |
MILLENNIUM MANAGEMENT LLC biological products, (no diagnostic substances) | 225.9K | 33.56% | 33.56% | $1.08B | Nov 14, 2025 | ▼ 358.5K |
FEDERATED HERMES, INC. biological products, (no diagnostic substances) | 210.0K | 31.19% | 31.19% | $999.60M | Nov 3, 2025 | ▼ 10.0K |
EDMOND DE ROTHSCHILD HOLDING S.A. biological products, (no diagnostic substances) | 203.3K | 30.20% | 30.20% | $967.87M | Nov 13, 2025 | — held |
数据来源：SEC 13F 申报文件。变动标识：isNew / isSoldOut / changeInSharesNumber。
机构仓位变动
Q3 2025 对比上季度
Q3 2025
13
增持
+1.60M 股9
新建仓
首次建仓8
减持
−464.6K 股3
清仓
完全退出净股数变化（前50家）
+1.14M
+1.60M / −464.6K
净新增持仓人
+11
新建 9 个 / 退出 3 个
基于前50家最大机构持仓统计，全市场实际数量可能不同。
内幕交易买卖情绪
SOPH 内幕交易记录
数据来源：SEC Form 4
近期内部人员以卖出为主。 卖出可能源于预定的 10b5-1 计划，不代表负面展望。
28
买入笔数
68
卖出笔数
0.41
买卖比
$0M
卖出总金额
最近内幕交易记录
最近10条 · 仅普通股
| 姓名 · 职位 | 日期 | 类型 | 股数 | 价格 | 金额 | 交易后持股 | 申报 |
|---|---|---|---|---|---|---|---|
CARDOZA GEORGE Chief Financial Officer | Jun 5, 2026 | Purchase | 20,000 | $4.95 | $99.0K | 311.5K | Form 4 ↗ |
Menu Philippe Chief Medical Officer | May 26, 2026 | Sale | 5,000 | $4.95 | $24.8K | 250.8K | Form 4 ↗ |
Muken Ross President | May 19, 2026 | Sale | 761 | $4.60 | $3.5K | 680.9K | Form 4 ↗ |
Xu Zhenyu Chief Scientific Officer | May 19, 2026 | Sale | 608 | $4.60 | $2.8K | 626.3K | Form 4 ↗ |
Camblong Jurgi Chief Executive Officer | May 19, 2026 | Sale | 4,486 | $4.60 | $20.7K | 3.63M | Form 4 ↗ |
Menu Philippe Chief Medical Officer | May 19, 2026 | Sale | 608 | $4.61 | $2.8K | 255.8K | Form 4 ↗ |
Van Well Daan Chief Legal Officer | May 19, 2026 | Sale | 684 | $4.60 | $3.1K | 345.1K | Form 4 ↗ |
Valente Manuela Chief People Officer | May 19, 2026 | Sale | 380 | $4.60 | $1.7K | 214.7K | Form 4 ↗ |
Puylaert Kevin Chief Sales Officer | May 19, 2026 | Sale | 33 | $4.54 | $149.899 | 148.2K | Form 4 ↗ |
Xu Zhenyu Chief Scientific Officer | May 13, 2026 | Sale | 4,000 | $4.54 | $18.2K | 626.9K | Form 4 ↗ |
数据来源：SEC Form 4。买卖方向：acquisitionOrDisposition A=买入，D=卖出。已排除 RSU 归属（M-Exempt）。
关于机构与内部人持股结构
SOPHiA GENETICS S.A.（SOPH）主要由机构投资者持有，机构持股比例约为 24.7%。公司内部人员持股约 27.84%，散户及公众持股约占剩余的 47.45%。
SOPHiA GENETICS S.A. 最大机构股东为 GENERATION INVESTMENT MANAGEMENT LLP，截至 September 30, 2025 持有约 6.79 million 股，占总流通股的 10.09%。
目前共有 40 家机构持有 SOPH 股票，合计持仓市值约 $84,309,953，数据来源为最新 SEC 13F 申报。
常见问题
SOPH ownershipSOPHiA GENETICS S.A.（SOPH）主要由机构投资者持有，机构持股约 24.7%。最大股东为 GENERATION INVESTMENT MANAGEMENT LLP，持股比例 10.09%。内部人员持股约 27.84%。数据来源 SEC Form 13F，截至 September 30, 2025。